Three More Biotechs Price Their Nasdaq IPOs
AgomAb Therapeutics, SpyGlass Pharma, and Veradermics have filed Nasdaq IPO pricing, each seeking $150‑200 million. AgomAb plans to sell 2.5 million shares at $15‑$17, targeting a post‑money valuation near $875 million. SpyGlass will issue 9.4 million shares at the same price range, aiming for a $550 million valuation, while Veradermics proposes 13.4 million shares at $14‑$16 for a valuation above $530 million. The three offerings raise the week’s priced biotech IPOs to four, signaling renewed investor confidence in mid‑ to late‑stage biotech firms after a 2024‑25 slump.
Janux Hires CMO After T Cell Engager Deal with Bristol Myers; A Batch of Appointments at Lexeo
Janux Therapeutics announced the appointment of William Go, M.D., Ph.D., as its new chief medical officer, replacing Zachariah McIver. The hire follows a recently disclosed partnership with Bristol Myers Squibb that provides a $50 million upfront payment for Janux’s T‑cell engager...
Politicization Runs Deeper than Ever at FDA, Risking Long-Term Impacts
The FDA has undergone an unprecedented wave of politicization in the past year, marked by mass staff departures, early retirements, and a surge of political appointees across senior roles. This shift has altered advisory committees, review processes, and introduced the...
Reed Jobs' Cancer Biotech Investment Firm Yosemite Eyes $350M Fund
Yosemite, the cancer‑research investment firm led by Reed Jobs, is seeking to raise a fund of up to $350 million. The capital target positions the firm among the largest early‑stage biotech funds currently forming. Jobs leverages his Silicon Valley connections and...
AI Battle: GPT-5, DeepSeek, Claude Tackle Dental MCQs
A recent study evaluated three leading AI models—GPT‑5, DeepSeek, and Claude—on multiple‑choice questions that simulate dental treatment scenarios for medically compromised patients. GPT‑5 delivered the most accurate and comprehensive answers, while DeepSeek excelled in localized problem solving but faltered on...
Metformin Shown to Prevent Long COVID Across Risk Groups in Multiple Randomized Trials
Multiple randomized trials and electronic‑health‑record analyses show that a 14‑day course of metformin, started during or shortly after acute SARS‑CoV‑2 infection, significantly lowers the risk of developing Long COVID. Across four studies, one Long COVID case is prevented for every...
Building a Smart Oncology Pipeline with Cumulus Oncology
Dr. Clare Wareing, founder and CEO of Cumulus Oncology, discussed the company’s risk‑adjusted preclinical pipeline aimed at high‑unmet‑need cancers. Cumulus employs a platform‑agnostic, precision‑medicine strategy that prioritizes patient subgroups to improve development success. The interview highlighted the supportive Scottish biotech...
Timing of Cord Blood Transplant Affects Graft Disease
Researchers have linked the circadian rhythm of soluble CD26 (sCD26) to acute graft‑versus‑host disease (aGVHD) risk in cord blood transplantation (CBT). Peak sCD26 levels suppress pathogenic T‑cell activity, creating a temporal window that lowers aGVHD incidence and severity. The team...
Systemic Immune-Inflammation Index Predicts Pediatric AKI Risk
A recent Pediatric Research study demonstrates that the systemic immune‑inflammation index (SII) predicts mortality in critically ill children with acute kidney injury (AKI). The researchers analyzed ICU data, finding that higher SII scores—reflecting neutrophilia, lymphopenia, and thrombocytosis—correlate with increased death...
Elusive Biomarkers Challenge Necrotizing Enterocolitis Diagnosis
Dr. Josef Neu’s recent article argues that reliable biomarkers for necrotizing enterocolitis (NEC) remain elusive due to the disease’s heterogeneity, methodological flaws in prior studies, and the unique physiology of preterm infants. He highlights that single‑molecule indicators such as cytokines...
Combating Salmonella and Listeria in Apple Juice
The U.S. Food and Drug Administration released new guidance on mitigating Salmonella and Listeria contamination in commercially bottled apple juice. The recommendations emphasize high‑temperature short‑time (HTST) pasteurization, routine environmental testing, and the adoption of antimicrobial hurdle technologies. Early adopters report...
Why ‘Natural’ Isn’t Enough: The Science of Pregnancy-Safe Skincare
Pregnancy fundamentally changes skin physiology, increasing permeability and absorption of topical ingredients, which means that products deemed safe for the general population may pose risks to mother and baby. The article debunks the myth that “natural” automatically equals safe, highlighting...
Transforming Healthcare Training for Autistic Clients
A coalition of health systems and autism advocacy groups launched a $12 million training program to equip clinicians with autism‑specific skills. The curriculum combines sensory‑friendly communication techniques, evidence‑based clinical guidelines, and virtual‑reality simulations. In a pilot across 15 hospitals, provider confidence...
DNA-Protein Crosslinks Drive Inflammation Linked to Early Aging
Researchers have shown that unrepaired DNA‑protein crosslinks (DPCs) provoke chronic inflammation via the cGAS‑STING pathway, leading to premature aging and embryonic lethality in mice. The study identifies the SPRTN protease as the key enzyme that resolves DPCs during replication and...
Multiply Labs Partners with Nvidia to Bring Physical AI Robotics to Advanced Biomanufacturing
Multiply Labs announced a partnership with Nvidia to embed the company's Isaac Sim, GR00T, FoundationPose and FoundationStereo technologies into its robotic biomanufacturing platform. The collaboration enables digital twins, AI‑driven manipulation models and perception pipelines that accelerate automation of cell and...
Hippocampal Replay Persists but Loses Structure in Alzheimer’s Model
Researchers at UCL found that hippocampal replay persists but loses structural coherence in an Alzheimer’s mouse model. While the frequency of replay events remained normal, the ordered activation of place cells was disrupted, leading to weakened co‑firing patterns. This neural...
Immunotherapy Reduces Plaque in Mouse Arteries, Suggesting Coronary Disease Intervention
Researchers at Washington University and Amgen created a bispecific T‑cell engager (BiTE) that selectively eliminates fibroblast activation protein (FAP)‑positive modulated smooth‑muscle cells in mouse atherosclerosis models. The treatment cut plaque burden, lowered inflammation, and enhanced plaque stability, suggesting a new...
Differential Protein Network and Biological Functions Atlas From Multi-Tissue Proteomics in Patients with Depression
A multi‑tissue proteomic atlas was generated from patients with major depressive disorder, revealing distinct protein interaction networks and tissue‑specific functional signatures. The study integrated label‑free mass spectrometry across brain, blood, and peripheral tissues, identifying over 5,000 quantified proteins and dozens...
AI Use in Breast Cancer Screening Cuts Rate of Later Diagnosis by 12%, Study Finds
A Swedish trial of 100,000 women showed that AI‑supported mammography cut later‑stage breast cancer diagnoses by 12% and boosted early detection to 81% of cases. The AI system triaged low‑risk scans to a single radiologist and flagged high‑risk scans for...
Prenosis Raises $20M Series A Round
Prenosis, a biology‑based technology company, closed a $20 million Series A financing round. The round was led by PACE Healthcare Capital with co‑investors including UC Investments, Labcorp Venture Fund and state entities. Simultaneously, Prenosis secured a BARDA contract to commercialize Sepsis ImmunoScore®,...
Spinal Cord Stimulation Eases Parkinson’s Gait Issues
A recent clinical trial found that spinal cord stimulation (SCS) significantly improves gait disturbances in Parkinson's disease patients. The study, involving 45 participants, reported a 30% increase in walking speed and a marked reduction in freezing episodes. Researchers implanted epidural...
EDTA-GUI: Advanced Plant Lineage Classification Made Easy
EDTA‑GUI launches as a web‑based platform that streamlines plant lineage classification using the Enhanced DNA‑Taxonomy Algorithm (EDTA). The tool delivers 96% accuracy across more than 1,200 reference genomes while processing datasets ten times faster than traditional command‑line pipelines. It bundles...
The AI Hype Index: Grok Makes Porn, and Claude Code Nails Your Job
MIT Technology Review’s AI Hype Index highlights the polarizing capabilities of emerging models. It notes that Meta’s Grok can generate pornographic material, while Anthropic’s Claude Code can build websites and interpret medical scans. The piece warns of a seismic impact...
Real-Time Imaging Captures Contact Between Cells and Between a Single Neuron's Extensions
Japanese researchers at Osaka University introduced Gachapin, a rapid‑acting fluorescent marker that lights up when cells touch and extinguishes when they separate. The tool overcomes split‑GFP’s slow, irreversible signal, enabling real‑time visualization of transient cell‑cell contacts. A single‑component variant, Gachapin‑C,...
ROSS Announces CDA-200 Dual Shaft Mixer for Processing Viscous Pharmaceuticals
ROSS introduced the CDA‑200 Dual Shaft Mixer, engineered for high‑viscosity pharmaceutical batches up to 500,000 cP and 200 gallons per run. The system pairs a 10‑hp anchor agitator with a high‑speed disperser, creating a vortex that rapidly wets dry ingredients and ensures...
Refractive-Index Microscope Measures a Sample's Optical Properties with Pinpoint Accuracy
Researchers at TU Wien have created a hybrid microscopy technique that merges single‑molecule localization microscopy with atomic force microscopy to directly measure the refractive index of biological samples at nanometer scales. By using AFM‑derived topography to decouple distance‑related blur from...
Tele-Coaching Boosts Self-Efficacy in Gestational Diabetes
A recent BMC Nursing study compared nursing‑led tele‑coaching with traditional in‑person nursing for women with gestational diabetes. Participants receiving tele‑coaching reported higher self‑efficacy, better adherence to diet and exercise, and improved glucose control. The intervention leveraged regular video consults, personalized...
Ruxolitinib: Second-Line Treatment for Bronchiolitis Obliterans
Ruxolitinib, a JAK1/2 inhibitor, is being evaluated as a second‑line therapy for bronchiolitis obliterans (BO) in patients who fail conventional steroids. A recent multicenter Phase II trial involving 48 post‑transplant recipients reported a 45% median improvement in forced expiratory volume...
Takeda 'Anticipated' Medicare Negotiations for Top Seller Entyvio
Takeda’s incoming CEO Julie Kim said the company anticipated Medicare’s selection of Entyvio for upcoming coverage negotiations. Entyvio, Takeda’s top-selling inflammatory‑bowel‑disease biologic, generated roughly $2.5 billion in 2023 revenue. While the firm expects a constructive dialogue, it has not disclosed pricing...
Electrographic Cue Reactivity Aligns with Accumbens DBS
A recent study demonstrates that electrographic cue reactivity measured in the nucleus accumbens aligns closely with clinical outcomes of deep brain stimulation (DBS) for addiction and mood disorders. Researchers recorded local field potentials while subjects were exposed to drug‑related cues...
Scalable In-Situ Fabrication of Multimodal E-Skin
Researchers led by Lim, Choi, and Han have introduced a scalable in‑situ fabrication method for multimodal electronic skin that integrates pressure, temperature, and strain sensors directly onto robotic surfaces. The process combines deposition and patterning in a single workflow, using...
Takeda Is ‘Not in Favor’ of Trump’s MFN Deals, CEO-Designate Says
Takeda’s incoming chief executive publicly stated that the company is not supportive of President Donald Trump’s proposed “most favored nation” (MFN) agreements with pharmaceutical manufacturers. The MFN framework would grant U.S. drugmakers preferential pricing and market‑access terms, a move Takeda...
Strawberry Cultivars’ Anthocyanins and Anti-Inflammatory Effects
A recent study examined the anthocyanin profiles of multiple strawberry cultivars and linked higher pigment concentrations to measurable anti‑inflammatory effects in vitro and in animal models. Researchers identified three cultivars with up to 45 % more anthocyanins than standard varieties, correlating...
The Disrupted Fate of Pharmacy Startups
The House Judiciary Committee released a report alleging that CVS Health engaged in antitrust practices to suppress disruptive pharmacy startups. The findings highlight potential collusion with insurers and pharmacy benefit managers to limit market entry. Industry observers note that the...
Bead-Free CAR T Cells Via Two-Stage Microfluidics
Researchers introduced a two‑stage inertial microfluidic platform that enriches activated T‑cells without magnetic beads. The label‑free approach separates cells by size, shape and deformability, delivering higher purity and viability for CAR‑T manufacturing. Compatibility with closed‑system GMP processes lowers contamination risk...
Nanoclay-Melon Protein Coatings Extend Mushroom Shelf Life
Researchers have created an edible nanoclay‑melon protein coating that dramatically prolongs the shelf life of fresh mushrooms. Laboratory tests showed the coating extended freshness by up to seven days and cut weight loss by roughly 40% compared with untreated produce....
Pipeline Cuts for Sanofi; Breakthru Medicine Raises $60M
Sanofi announced a broad portfolio review that will cut several late‑stage drug programs, aiming to streamline its pipeline and improve cost efficiency. The cull affects multiple candidates across therapeutic areas, though specific names were not disclosed. In parallel, Breakthru Medicine...
Breakthru Medicine Raises $60M in Series A Funding
Breakthru Medicine, a Phoenix‑based oncology startup, announced a $60 million Series A round led by a board of seasoned investors including Dave Morehead, Fred Eshelman and Mark Gergen. The capital will fund expansion of its precision‑therapy platform targeting solid tumors deemed “undruggable.” Breakthru’s pipeline...
Summit Says FDA Will Decide to Approve Its Cancer Drug by November
Summit Therapeutics announced that the U.S. Food and Drug Administration has set a target date of November 2024 to render a decision on its flagship cancer immunotherapy. The drug, positioned as a next‑generation immuno‑oncology agent, has completed its pivotal Phase III...
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
Biotech is emerging from a multi‑year slump into a new cycle driven by late‑stage, asset‑centric deals, as highlighted at JPM 2026. While headline megadeals were scarce, rumors around Revolution Medicines and Abivax and announced transactions such as Eli Lilly‑Ventyx and GSK‑RAPT underscored...
Type 2 Diabetes and Liver Disease in Tanzania: Insights
A Tanzanian cohort study found that 30% of patients with type 2 diabetes exhibit metabolic dysfunction‑associated steatotic liver disease (MASLD). Obesity, high‑calorie diets and physical inactivity emerged as the strongest predictors, while hypertension and dyslipidemia frequently co‑occurred. The research highlights a...
Is Platelet-to-Neutrophil Ratio Key for Sickle Cell Care?
A recent multicenter study proposes the platelet‑to‑neutrophil ratio (PNR) as a novel biomarker for managing sickle cell disease. Researchers found that patients with elevated PNR experienced more frequent vaso‑occlusive crises and higher hospitalization rates. The ratio, derived from a routine...
Cost Analysis of Obesity Treatment in Iran
Iran’s obesity prevalence has risen to about 25%, driving a sharp increase in treatment demand and costs. Direct medical spending on obesity now exceeds 1% of the national health budget, with bariatric surgery accounting for nearly half of that outlay....
AstraZeneca Pledges $15B More in Chinese Investments for Cell Therapies, Radiopharma
AstraZeneca announced a $15 billion investment in its China operations through 2030, aimed at bolstering capabilities in cell therapies and radioconjugates. The funding will support the full drug development chain, from design to manufacturing, and expand existing production sites in Wuxi,...
Sanofi Suffers Another Sales Dip For 'Gift to Public Health' Vaccines
Sanofi reported a 2.5% decline in 2025 vaccine revenue to €2 bn, marking a continued sales dip amid rising U.S. vaccine skepticism. The drop was offset by a 31.5% surge in flu and COVID‑19 vaccine sales, driven by higher virus circulation...
Barbados Government and BioMed X Partner to Improve AI-Based Early Diabetic Kidney Disease Modeling
BioMed X, a German pharma innovation hub, has teamed up with the Barbados government and the EU’s PharmaNext programme to launch an AI‑enabled research initiative targeting early diabetic kidney disease in the island’s type‑2 diabetes population. The project will combine...
Sleep Disturbance and Mobile Phone Use: Network Links
A recent study employing network analysis links mobile phone usage patterns to sleep disturbance. The research finds that high-frequency nighttime screen time, especially blue‑light exposure, is the strongest predictor of reduced sleep duration and poorer sleep quality. Young adults and...
Roche Predicts Its Breast Cancer Pill Could Become Its Biggest-Selling Drug
Roche’s oral breast‑cancer therapy is gaining momentum after two positive late‑stage trial readouts demonstrated strong efficacy and tolerable safety. The company has submitted a U.S. FDA filing and expects a decision later this year. An additional pivotal trial will report...
Following Abivax, Formation Bio Licenses miR-124 Drug From China
Formation Bio announced a licensing agreement to acquire rights to a miR‑124‑based drug candidate from a Chinese partner, mirroring the target of French biotech Abivax’s recently successful ulcerative colitis therapy. The deal positions Formation Bio to enter the rapidly expanding...
Sanofi Says Its €15B Dealmaking Budget, R&D Spend Should Help Ease Looming Dupixent Patent Cliff
Sanofi announced a €14‑15 billion budget for mergers and acquisitions in 2026, alongside a bolstered R&D spend of roughly €7 billion. The pharmaceutical giant aims to counter the looming revenue gap from Dupixent’s patent expiration expected around 2027. Management expects the combined...